

# Fabio Farinati

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3805384/publications.pdf>

Version: 2024-02-01

342  
papers

15,211  
citations

18436

62  
h-index

25716

108  
g-index

347  
all docs

347  
docs citations

347  
times ranked

13330  
citing authors

#	ARTICLE	IF	CITATIONS
1	A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. <i>Hepatology</i> , 1998, 28, 751-755.	3.6	1,271
2	Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness. <i>American Journal of Gastroenterology</i> , 2008, 103, 914-921.	0.2	429
3	Diagnostic and Prognostic Role of alpha-Fetoprotein in Hepatocellular Carcinoma: Both or Neither?. <i>American Journal of Gastroenterology</i> , 2006, 101, 524-532.	0.2	391
4	Prospective validation of the Barcelona Clinic Liver Cancer staging system. <i>Journal of Hepatology</i> , 2006, 44, 723-731.	1.8	378
5	Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. <i>Journal of Hepatology</i> , 1995, 22, 449-456.	1.8	365
6	Liver Transplantation for the Treatment of Moderately or Well-Differentiated Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2004, 239, 150-159.	2.1	289
7	Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). <i>American Journal of Gastroenterology</i> , 2002, 97, 734-744.	0.2	282
8	Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. <i>Journal of Hepatology</i> , 2010, 53, 291-297.	1.8	281
9	Gastric epithelial dysplasia in the natural history of gastric cancer: A multicenter prospective follow-up study. <i>Gastroenterology</i> , 1994, 107, 1288-1296.	0.6	240
10	Oxidative DNA damage accumulation in gastric carcinogenesis. <i>Gut</i> , 1998, 42, 351-356.	6.1	235
11	Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. <i>Hepatology</i> , 2020, 72, 1864-1872.	3.6	221
12	Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. , 1999, 85, 2132-2137.		216
13	Association between reactive oxygen species and disease activity in chronic hepatitis C. <i>Free Radical Biology and Medicine</i> , 1996, 21, 291-295.	1.3	206
14	Prognosis of untreated hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 184-190.	3.6	188
15	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 617-624.	1.8	184
16	The long term outcome of gastric non-invasive neoplasia. <i>Gut</i> , 2003, 52, 1111-1116.	6.1	167
17	Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2013, 45, 712-723.	0.4	155
18	How should patients with hepatocellular carcinoma be staged?. <i>Cancer</i> , 2000, 89, 2266-2273.	2.0	153

#	ARTICLE	IF	CITATIONS
19	Autoimmune gastritis: Pathologist's viewpoint. <i>World Journal of Gastroenterology</i> , 2015, 21, 12179.	1.4	149
20	Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. <i>Gut</i> , 2010, 59, 387-396.	6.1	145
21	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. <i>Lancet Oncology</i> , The, 2011, 12, 654-662.	5.1	135
22	Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. <i>Hepatology</i> , 2012, 56, 1371-1379.	3.6	130
23	Surveillance for Hepatocellular Carcinoma in Elderly Italian Patients With Cirrhosis: Effects on Cancer Staging and Patient Survival. <i>American Journal of Gastroenterology</i> , 2004, 99, 1470-1476.	0.2	116
24	Re: CDX2 Homeotic Gene Expression in Gastric Noninvasive Neoplasia. <i>American Journal of Surgical Pathology</i> , 2004, 28, 834-835.	2.1	115
25	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016, 13, e1002006.	3.9	113
26	Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection. <i>Free Radical Biology and Medicine</i> , 1999, 27, 1284-1291.	1.3	112
27	Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. <i>World Journal of Gastroenterology</i> , 2011, 17, 4596.	1.4	112
28	Intention-to-Treat Analysis of Liver Transplantation in Selected, Aggressively Treated HCC Patients Exceeding the Milan Criteria. <i>American Journal of Transplantation</i> , 2007, 7, 972-981.	2.6	111
29	Surveillance for Early Diagnosis of Hepatocellular Carcinoma: Is It Effective in Intermediate/Advanced Cirrhosis?. <i>American Journal of Gastroenterology</i> , 2007, 102, 2448-2457.	0.2	110
30	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 333-341.	1.8	110
31	Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. <i>Journal of Hepatology</i> , 1990, 11, 297-301.	1.8	108
32	Factors That Affect Efficacy of Ultrasound Surveillance for Early Stage Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1927-1933.e2.	2.4	108
33	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. <i>Hepatology</i> , 2020, 72, 2206-2218.	3.6	107
34	Guidelines for the management of <i>Helicobacter pylori</i> infection in Italy: The III Working Group Consensus Report 2015. <i>Digestive and Liver Disease</i> , 2015, 47, 903-912.	0.4	106
35	Autoimmune gastritis: histology phenotype and <sc>OLGA</sc> staging. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1460-1466.	1.9	101
36	The role of cysteine and serine proteases in colorectal carcinoma. <i>Cancer</i> , 1999, 86, 1135-1142.	2.0	97

#	ARTICLE	IF	CITATIONS
37	DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. <i>Journal of Hepatology</i> , 2001, 34, 587-592.	1.8	96
38	OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. <i>American Journal of Gastroenterology</i> , 2018, 113, 1621-1628.	0.2	96
39	Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: Comparative analysis from two centers. <i>Hepatology</i> , 2009, 50, 1162-1168.	3.6	93
40	Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety. <i>Hepatology</i> , 2010, 51, 165-173.	3.6	93
41	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. <i>Hepatology</i> , 2018, 67, 1784-1796.	3.6	93
42	Gastric epithelial dysplasia: A prospective multicenter follow-up study from the interdisciplinary group on gastric epithelial dysplasia. <i>Human Pathology</i> , 1991, 22, 1002-1008.	1.1	91
43	Early and Advanced Gastric Cancer in the Follow-Up of Moderate and Severe Gastric Dysplasia Patients. A Prospective Study. <i>Endoscopy</i> , 1993, 25, 261-264.	1.0	91
44	The changing scenario of hepatocellular carcinoma over the last two decades in Italy. <i>Journal of Hepatology</i> , 2012, 56, 397-405.	1.8	84
45	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 65-71.	1.8	83
46	Effect of the Etiology of Viral Cirrhosis on the Survival of Patients with Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2006, 101, 91-98.	0.2	81
47	Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. <i>BMC Cancer</i> , 2008, 8, 194.	1.1	80
48	Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. <i>BMC Cancer</i> , 2009, 9, 33.	1.1	79
49	Gastric Antioxidant, Nitrites, and Mucosal Lipoperoxidation in Chronic Gastritis and <i>Helicobacter pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 1996, 22, 275-281.	1.1	79
50	Hepatic and extrahepatic malignancies in primary biliary cirrhosis. <i>Hepatology</i> , 1999, 29, 1425-1428.	3.6	74
51	Pathology of the gastric antrum and body associated with <i>Helicobacter pylori</i> infection in non-ulcerous patients: is the bacterium a promoter of intestinal metaplasia?. <i>Histopathology</i> , 1993, 22, 9-16.	1.6	71
52	Unresectable hepatocellular carcinoma in cirrhosis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 2332-2339.	1.1	71
53	<i>Helicobacter pylori</i> , inflammation, oxidative damage and gastric cancer: a morphological, biological and molecular pathway. <i>European Journal of Cancer Prevention</i> , 2008, 17, 195-200.	0.6	71
54	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 1157-1166.	1.9	70

#	ARTICLE	IF	CITATIONS
55	Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis. <i>Human Pathology</i> , 2017, 65, 62-70.	1.1	70
56	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of <scp>HCV</scp> eradication does not depend on the use of interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 160-168.	1.9	70
57	Prevalence and Prognostic Significance of the Presence of Esophageal Varices in Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1378-1384.	2.4	69
58	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021, 41, 585-597.	1.9	69
59	Gastric epithelial dysplasia. How clinicopathologic background relates to management. <i>Cancer</i> , 1995, 76, 376-382.	2.0	67
60	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2017, 37, 259-270.	1.9	67
61	The Effects of Chronic Ethanol Consumption on Carcinogen Metabolism and on O6-Methylguanine Transferase-Mediated Repair of Alkylated DNA. <i>Alcoholism: Clinical and Experimental Research</i> , 1986, 10, 73S-77S.	1.4	66
62	Hepatocellular carcinoma in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1994, 21, 315-316.	1.8	66
63	<i>Helicobacter pylori</i> CagA Status, Mucosal Oxidative Damage and Gastritis Phenotype: A Potential Pathway to Cancer?. <i>Helicobacter</i> , 2003, 8, 227-234.	1.6	66
64	A new approach to the use of $\alpha$ -fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. <i>British Journal of Cancer</i> , 2015, 112, 69-76.	2.9	66
65	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2017, 49, 440-445.	0.4	66
66	Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. <i>Molecular Cancer</i> , 2007, 6, 17.	7.9	64
67	Fas $\alpha$ system, IL $\beta$ expression and apoptosis in chronic HBV and HCV liver disease. <i>Journal of Viral Hepatitis</i> , 2008, 15, 515-522.	1.0	63
68	Oxidative DNA damage in gastric cancer: CagA status and OGG1 gene polymorphism. <i>International Journal of Cancer</i> , 2008, 123, 51-55.	2.3	61
69	Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. <i>Journal of Hepatology</i> , 2012, 56, 1089-1096.	1.8	61
70	Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. <i>Hepatology International</i> , 2013, 7, 1050-1057.	1.9	59
71	Comparison between alcohol $\alpha$ -and hepatitis C virus $\alpha$ -related hepatocellular carcinoma: clinical presentation, treatment and outcome. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 385-399.	1.9	59
72	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2016, 111, 70-77.	0.2	59

#	ARTICLE	IF	CITATIONS
73	When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. <i>Digestive and Liver Disease</i> , 2018, 50, 640-646.	0.4	59
74	Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1992, 37, 659-662.	1.1	58
75	Oxidative damage in the progression of chronic liver disease to hepatocellular carcinoma: An intricate pathway. <i>World Journal of Gastroenterology</i> , 2014, 20, 3078.	1.4	58
76	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002â€“2033: the ITA.LI.CA database. <i>Gut</i> , 2023, 72, 141-152.	6.1	57
77	Determinants of alphaâ€“fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. <i>Cancer</i> , 2014, 120, 2150-2157.	2.0	56
78	Proteases in gastrointestinal neoplastic diseases. <i>Clinica Chimica Acta</i> , 2000, 291, 171-187.	0.5	54
79	Impact of Etiology of Cirrhosis on the Survival of Patients Diagnosed With Hepatocellular Carcinoma During Surveillance. <i>CME. American Journal of Gastroenterology</i> , 2007, 102, 1022-1031.	0.2	54
80	Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma. <i>BMC Cancer</i> , 2012, 12, 177.	1.1	54
81	Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. <i>Future Oncology</i> , 2013, 9, 283-294.	1.1	54
82	Cysteine and serine proteases in gastric cancer. <i>Cancer</i> , 1995, 76, 367-375.	2.0	53
83	Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. <i>British Journal of Cancer</i> , 2019, 121, 257-263.	2.9	53
84	Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1065-1070.	0.8	51
85	Validation of the BCLC Prognostic System in Surgical Hepatocellular Cancer Patients. <i>Transplantation Proceedings</i> , 2009, 41, 1260-1263.	0.3	51
86	Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1212-1218.	0.8	51
87	Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2011, 117, 125-133.	2.0	51
88	Tamoxifen in the Treatment of Hepatocellular Carcinoma: 5-Year Results of the CLIP-1 Multicentre Randomised Controlled Trial. <i>Current Pharmaceutical Design</i> , 2002, 8, 1013-1019.	0.9	50
89	Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 821-829.	1.0	49
90	Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2012, 12, 118.	0.8	49

#	ARTICLE	IF	CITATIONS
91	The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. <i>Human Pathology</i> , 2013, 44, 1804-1810.	1.1	49
92	Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 243-249.	2.0	48
93	Hepatocellular Carcinoma in Patients With Cryptogenic Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 580-585.	2.4	48
94	Advanced precancerous lesions in the liver. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 269-284.	1.0	46
95	Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. <i>Liver International</i> , 2013, 33, 1594-1600.	1.9	46
96	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. <i>Liver Transplantation</i> , 2017, 23, 1103-1112.	1.3	46
97	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 423-433.	1.9	46
98	HBV and HCV infections in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 718-724.	0.3	45
99	Gastrointestinal stromal tumors: report of an audit and review of the literature. <i>European Journal of Cancer Prevention</i> , 2009, 18, 106-116.	0.6	45
100	Oxidative Stress and Inducible Nitric Oxide Synthase Induction in Carcinogenesis. <i>Digestive Diseases</i> , 2010, 28, 579-584.	0.8	45
101	Barrett's Esophagus and Adenocarcinoma Risk. <i>Annals of Surgery</i> , 2012, 256, 788-795.	2.1	45
102	Long-Term Follow-up of Barrett's Epithelium: Medical Versus Antireflux Surgical Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 7-15.	0.9	45
103	Diagnostic and prognostic role of SCCA and IgM serum levels in hepatocellular carcinoma (HCC). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1637-1644.	1.4	44
104	Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. <i>Clinical and Experimental Metastasis</i> , 1997, 15, 418-426.	1.7	43
105	The survival benefit of liver transplantation in hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2010, 42, 642-649.	0.4	42
106	Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. <i>Journal of Personalized Medicine</i> , 2021, 11, 1095.	1.1	42
107	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. <i>Liver International</i> , 2015, 35, 223-231.	1.9	41
108	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , 2019, 39, 1478-1489.	1.9	41

#	ARTICLE	IF	CITATIONS
109	Association of Abnormal Plasma Bilirubin With Aggressive Hepatocellular Carcinoma Phenotype. <i>Seminars in Oncology</i> , 2014, 41, 252-258.	0.8	40
110	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. <i>Digestive and Liver Disease</i> , 2014, 46, 579-589.	0.4	40
111	Anti-HCV positive hepatocellular carcinoma in cirrhosis. <i>Journal of Hepatology</i> , 1992, 14, 183-187.	1.8	39
112	The "three-in-one" formulation of bismuth quadruple therapy for <i>Helicobacter pylori</i> eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice. <i>Helicobacter</i> , 2018, 23, e12502.	1.6	39
113	Effects of coffee consumption in chronic hepatitis C: A randomized controlled trial. <i>Digestive and Liver Disease</i> , 2013, 45, 499-504.	0.4	38
114	Hepatocellular carcinoma in patients without cirrhosis in Italy. <i>Digestive and Liver Disease</i> , 2013, 45, 164-169.	0.4	38
115	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 859-871.	0.9	38
116	Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis. <i>Carcinogenesis</i> , 1996, 17, 2581-2587.	1.3	37
117	HEPATOCTE PROLIFERATION AND APOPTOSIS IN RELATION TO OXIDATIVE DAMAGE IN ALCOHOL-RELATED LIVER DISEASE. <i>Alcohol and Alcoholism</i> , 2002, 37, 43-48.	0.9	37
118	Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclonal antibody MIB1 Ki67 in archival material: The role of etiology, disease activity, iron, and lipid peroxidation. <i>Hepatology</i> , 1996, 23, 1468-1475.	3.6	37
119	Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 500.	1.8	37
120	Changes in Parietal and Mucous Cell Mass in the Gastric Mucosa of Normal Subjects with Age: A Morphometric Study. <i>Gerontology</i> , 1993, 39, 146-151.	1.4	36
121	Pathology and ploidy in the prognosis of gastric cancer with no extranodal metastasis. <i>Cancer</i> , 1994, 73, 1127-1133.	2.0	36
122	Operative Link for Gastritis Assessment gastritis staging incorporates intestinal metaplasia subtyping. <i>Human Pathology</i> , 2011, 42, 1539-1544.	1.1	36
123	Tryptophan Hydroxylase Autoantibodies as Markers of a Distinct Autoimmune Gastrointestinal Component of Autoimmune Polyendocrine Syndrome Type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 704-712.	1.8	36
124	Significance of Platelet and AFP Levels and Liver Function Parameters for HCC Size and Survival. <i>International Journal of Biological Markers</i> , 2014, 29, 215-223.	0.7	36
125	Laparoscopic microwave ablation in patients with hepatocellular carcinoma: a prospective cohort study. <i>Hpb</i> , 2014, 16, 979-986.	0.1	36
126	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 296-304.	0.8	36



#	ARTICLE	IF	CITATIONS
127	Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer. <i>Digestive and Liver Disease</i> , 2002, 34, 794-801.	0.4	34
128	Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2005, 42, 728-735.	1.8	33
129	A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>Annals of Oncology</i> , 2000, 11, 1309-1312.	0.6	32
130	Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease. <i>Translational Research</i> , 2003, 141, 372-377.	2.4	32
131	Complications of radiofrequency thermal ablation in hepatocellular carcinoma: what about "explosive" spread?. <i>Gut</i> , 2006, 55, 435-436.	6.1	32
132	Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). <i>Digestive and Liver Disease</i> , 2010, 42, 831-838.	0.4	31
133	Hepatocellular carcinoma, alcohol, and cirrhosis: Facts and hypotheses. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1137-1142.	1.1	30
134	Non-invasive neoplasia of the stomach. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1191-1196.	0.8	30
135	Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 493-501.	1.9	30
136	Liver histopathology in COVID-19 patients: A mono-Institutional series of liver biopsies and autopsy specimens. <i>Pathology Research and Practice</i> , 2021, 221, 153451.	1.0	30
137	Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology study Section of the Italian Society of Gastroenterology (SIGE). <i>Digestive and Liver Disease</i> , 2001, 33, 217-221.	0.4	29
138	Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. <i>Thrombosis Research</i> , 2016, 143, 118-121.	0.8	29
139	Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2007, 95, 213-220.	0.8	28
140	Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. <i>European Journal of Cancer Prevention</i> , 2008, 17, 438-445.	0.6	28
141	A Liver Index and its Relationship to Indices of HCC Aggressiveness. <i>Journal of Integrative Oncology</i> , 2016, 5, .	0.3	28
142	Oxidative damage, pro-inflammatory cytokines, TGF- $\beta$ and c-myc in chronic HCV-related hepatitis and cirrhosis. <i>World Journal of Gastroenterology</i> , 2006, 12, 2065.	1.4	28
143	Effects of Chronic Ethanol Consumption on Carcinogen Activating and Detoxifying Systems in Rat Upper Alimentary Tract Tissue. <i>Alcoholism: Clinical and Experimental Research</i> , 1989, 13, 357-360.	1.4	27
144	Barrett's Epithelium After Antireflux Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 1253-1261.	0.9	27

#	ARTICLE	IF	CITATIONS
145	<sc>PD</sc> overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. <i>Histopathology</i> , 2017, 71, 470-474.	1.6	27
146	Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease. <i>Journal of Viral Hepatitis</i> , 2001, 8, 34-40.	1.0	27
147	CA 19-9 determination in gastric justice: Role in identifying gastric cancer and high risk patients. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1988, 24, 923-927.	0.9	26
148	Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. <i>Gastroenterology</i> , 2004, 126, 382-383.	0.6	26
149	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018, 68, 1232-1244.	3.6	26
150	MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. <i>Pathology Research and Practice</i> , 2018, 214, 835-839.	1.0	26
151	Let-7c down-regulation in <i>Helicobacter pylori</i> -related gastric carcinogenesis. <i>Oncotarget</i> , 2016, 7, 4915-4924.	0.8	26
152	Estrogens receptors and oxidative damage in the liver. <i>Molecular and Cellular Endocrinology</i> , 2002, 193, 85-88.	1.6	25
153	The Veneto Region's Barrett's Oesophagus Registry: Aims, methods, preliminary results. <i>Digestive and Liver Disease</i> , 2007, 39, 18-25.	0.4	25
154	Effect of Age on Gastric Acid, Pepsin, Pepsinogen Group A and Gastrin Secretion in Peptic Ulcer Patients. <i>Gerontology</i> , 1994, 40, 253-259.	1.4	24
155	Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype. <i>Journal of Clinical Pathology</i> , 2007, 60, 615-621.	1.0	24
156	Laparoscopic Ablation of Hepatocellular Carcinoma in Cirrhotic Patients Unsuitable for Liver Resection or Percutaneous Treatment: A Cohort Study. <i>PLoS ONE</i> , 2013, 8, e57249.	1.1	24
157	PD-L1 expression in gastroesophageal dysplastic lesions. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 151-156.	1.4	24
158	Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. <i>Digestive and Liver Disease</i> , 2011, 43, 875-80.	0.4	23
159	Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. <i>American Journal of Clinical Pathology</i> , 2017, 147, 301-308.	0.4	23
160	Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. <i>International Journal of Biological Markers</i> , 2018, 33, 423-431.	0.7	23
161	Risk of COVID-19 in celiac disease patients. <i>Autoimmunity Reviews</i> , 2020, 19, 102639.	2.5	23
162	Chemoprevention of colorectal cancer: feasibility in everyday practice?. <i>European Journal of Cancer Prevention</i> , 2008, 17, 502-514.	0.6	22

#	ARTICLE	IF	CITATIONS
163	Lesions Indefinite for Intraepithelial Neoplasia and OLGA Staging for Gastric Atrophy. American Journal of Clinical Pathology, 2012, 137, 727-732.	0.4	22
164	Sex hormone profile and endometrial cancer risk in primary biliary cirrhosis: a case-control study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2002, 103, 154-157.	0.5	21
165	Non-invasive diagnosis of Helicobacter pylori infection: simplified 13C-urea breath test, stool antigen testing, or DNA PCR in human feces in a clinical laboratory setting?. Clinical Biochemistry, 2004, 37, 261-267.	0.8	21
166	Gastrointestinal stromal tumors: The histology report. Digestive and Liver Disease, 2011, 43, S304-S309.	0.4	21
167	TACE treatment in hepatocellular carcinoma: What should we do now?. Journal of Hepatology, 2012, 57, 221-222.	1.8	21
168	Oxidative DNA Damage in Barrett Mucosa: Correlation with Telomeric Dysfunction and p53 Mutation. Annals of Surgical Oncology, 2013, 20, 583-589.	0.7	21
169	Low Alpha-Fetoprotein HCC and the Role of GGTP. International Journal of Biological Markers, 2014, 29, 395-402.	0.7	21
170	Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. Journal of Viral Hepatitis, 2017, 24, 1168-1176.	1.0	21
171	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. Cancers, 2021, 13, 1150.	1.7	21
172	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers, 2021, 13, 1673.	1.7	21
173	Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?. Cancers, 2021, 13, 2274.	1.7	21
174	Is Mild Gastric Epithelial Dysplasia an Indication for Follow-Up?. Journal of Clinical Gastroenterology, 1983, 5, 307-310.	1.1	20
175	Gastrin. European Journal of Cancer Prevention, 2014, 23, 258-263.	0.6	20
176	Years of life that could be saved from prevention of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2016, 43, 814-824.	1.9	20
177	Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. Journal of Viral Hepatitis, 2020, 27, 188-194.	1.0	20
178	Carcinoembryonic antigen in gastric juice collected during endoscopy. Value in detecting high-risk patients and gastric cancer. Cancer, 1983, 52, 2334-2337.	2.0	19
179	Follow-up in Gastric Dysplasia Patients. American Journal of Surgical Pathology, 1989, 13, 173.	2.1	19
180	Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. Translational Research, 2016, 168, 122-133.	2.2	19

#	ARTICLE	IF	CITATIONS
181	Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: Results of 815 procedures. <i>Journal of Surgical Oncology</i> , 2019, 120, 956-965.	0.8	19
182	Zinc, iron, and peroxidation in liver tissue. <i>Biological Trace Element Research</i> , 1995, 47, 193-199.	1.9	18
183	Hepatic spleen nodules (HSN). <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 628-632.	0.6	18
184	Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. <i>Digestive and Liver Disease</i> , 2019, 51, 1713-1719.	0.4	18
185	Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. <i>Scientific Reports</i> , 2019, 9, 3781.	1.6	18
186	Medical and gastroenterological education during the COVID-19 outbreak. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 447-449.	8.2	18
187	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13542.	1.7	18
188	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. <i>World Journal of Hepatology</i> , 2018, 10, 231-245.	0.8	18
189	Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. <i>Pathology Research and Practice</i> , 2020, 216, 152907.	1.0	17
190	Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 1097.	0.8	17
191	Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. <i>Liver International</i> , 2022, 42, 1229-1240.	1.9	17
192	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , 2021, 5, 1987-2000.	2.0	16
193	Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1495-1501.	1.9	15
194	Bax Inhibitor-1 down-regulation in the progression of chronic liver diseases. <i>BMC Gastroenterology</i> , 2010, 10, 35.	0.8	15
195	Liver transplantation for hepatocellular carcinoma in clinical practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 195-202.	0.8	15
196	Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study. <i>Liver International</i> , 2017, 37, 1184-1192.	1.9	15
197	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , 2021, 13, 4882.	1.7	15
198	SARS-CoV-2 and hepatitis. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 473-475.	0.5	15

#	ARTICLE	IF	CITATIONS
199	Re: CDX2 homeotic gene expression in gastric noninvasive neoplasia. American Journal of Surgical Pathology, 2004, 28, 834-5; author reply 835.	2.1	15
200	Identification of Two Clinical Hepatocellular Carcinoma Patient Phenotypes From Results of Standard Screening Parameters. Seminars in Oncology, 2014, 41, 406-414.	0.8	14
201	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. Translational Oncology, 2019, 12, 282-291.	1.7	14
202	Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective?. European Journal of Cancer Prevention, 2001, 10, 111-115.	0.6	14
203	Clinical markers of slow healing and relapsing gastric ulcer.. Gut, 1987, 28, 210-215.	6.1	13
204	CA 50 Determination in body fluids: Can we screen patients at risk for gastric cancer?. International Journal of Cancer, 1991, 47, 7-11.	2.3	13
205	Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination. Cancer Immunology, Immunotherapy, 2011, 60, 1057-1060.	2.0	13
206	Rise and fall of <sc>HCV</sc>-related hepatocellular carcinoma in Italy: a long-term survey from the <sc>ITA</sc>. <sc>LI</sc>. <sc>CA</sc> centres. Liver International, 2013, 33, 1420-1427.	1.9	13
207	From Barrett metaplasia to esophageal adenocarcinoma: the molecular background. Histology and Histopathology, 2016, 31, 25-32.	0.5	13
208	Diagnosis of gastric carcinoma in Japan and western countries. Lancet, The, 1997, 350, 448.	6.3	12
209	Sorafenib use in the transplant setting. Liver Transplantation, 2014, 20, 1021-1028.	1.3	12
210	Changes in micro<sc>RNA</sc> expression during disease progression in patients with chronic viral hepatitis. Liver International, 2015, 35, 1324-1333.	1.9	12
211	Upper gastrointestinal injury caused by diquat. Gastrointestinal Endoscopy, 1992, 38, 204.	0.5	11
212	Re: Helicobacter pylori and Atrophic Gastritis: Importance of the cagA Status. Journal of the National Cancer Institute, 1996, 88, 762-763.	3.0	11
213	Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis?. European Journal of Gastroenterology and Hepatology, 2001, 13, 1217-1224.	0.8	11
214	Molecular characterization of sessile serrated adenoma to carcinoma transition in six early colorectal cancers. Pathology Research and Practice, 2019, 215, 957-962.	1.0	11
215	Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions. International Journal of Molecular Sciences, 2021, 22, 9950.	1.8	11
216	Micronuclei and broken eggs in human liver carcinogenesis. Anticancer Research, 2008, 28, 2507-11.	0.5	11

#	ARTICLE	IF	CITATIONS
217	Occurrence of an atypical alkaline phosphatase fraction (â€œbiliaryâ€œ) in primary liver cancer. <i>Clinical Biochemistry</i> , 1983, 16, 346-349.	0.8	10
218	The mechanisms underlying hepatitis C virus genotype 3-mediated liver damage. <i>Journal of Hepatology</i> , 2003, 39, 292-294.	1.8	10
219	Hepatitis B virus-related hepatocellular carcinoma. <i>European Journal of Cancer Prevention</i> , 2011, 20, 381-388.	0.6	10
220	Alpha-fetoprotein in hepatocellular carcinoma surveillance: Wake not the dead. <i>Hepatology</i> , 2011, 54, 376-377.	3.6	10
221	Immunotherapy for gastric premalignant lesions and cancer. <i>Immunotherapy</i> , 2012, 4, 587-599.	1.0	10
222	Risk factors associated with hepatocellular carcinoma in primary biliary cirrhosis. <i>Hepatology</i> , 2013, 58, 1520-1521.	3.6	10
223	Utilityâ€based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alphaâ€fetoprotein model as a survival predictor. <i>Liver Transplantation</i> , 2015, 21, 1250-1258.	1.3	10
224	Trend of Improving Prognosis of Hepatocellular Carcinoma in Clinical Practice: An Italian In-Field Experience. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1465-1473.	1.1	10
225	Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. <i>Liver International</i> , 2018, 38, 1770-1776.	1.9	10
226	Metabolic disorders across hepatocellular carcinoma in Italy. <i>Liver International</i> , 2018, 38, 2028-2039.	1.9	10
227	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021, 41, 396-407.	1.9	10
228	Epithelial Dysplasia in Endoscopic Gastric Mucosal Biopsies. <i>Tumori</i> , 1981, 67, 589-598.	0.6	9
229	Perendoscopic gastric pH determination. <i>Gastrointestinal Endoscopy</i> , 1987, 33, 293-297.	0.5	9
230	Megestrol treatment in patients with hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2001, 85, 1606-1607.	2.9	9
231	Pathology and cost effectiveness of endoscopy surveillance for premalignant gastric lesions. <i>Gut</i> , 2003, 52, 453-454.	6.1	9
232	Fatal HBV-Related Liver Failure during Lamivudine Therapy in a Patient with Non-Hodgkin's Lymphoma. <i>Tumori</i> , 2008, 94, 748-749.	0.6	9
233	Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 401-406.	1.1	9
234	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897.	1.7	9

#	ARTICLE	IF	CITATIONS
235	A nomogram to predict overall survival and disease-free survival after curative-intent gastrectomy for gastric cancer. <i>Updates in Surgery</i> , 2021, 73, 1879-1890.	0.9	9
236	Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. <i>Liver International</i> , 2011, 31, 192-196.	1.9	8
237	BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. <i>Histopathology</i> , 2017, 71, 1008-1011.	1.6	8
238	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. <i>International Journal of Biological Markers</i> , 2021, 36, 54-61.	0.7	8
239	Gastric mucosa-associated lymphoid tissue lymphoma and <i>Helicobacter pylori</i> : Scratch and win. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 115-119.	0.6	7
240	Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre- and sorafenib era. <i>Hepatology Research</i> , 2010, 40, 153-160.	1.8	7
241	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019.	0.4	7
242	Treatment allocation in patients with hepatocellular carcinoma: Need for a paradigm shift?. <i>Liver Cancer International</i> , 2022, 3, 34-36.	0.2	7
243	Mutagenic activity in gastric juice and urine of subjects with chronic atrophic gastritis, gastric epithelial dysplasia and gastric cancer. <i>Cancer Letters</i> , 1989, 48, 169-175.	3.2	6
244	Serum and salivary caffeine clearance in cirrhosis. Any role in selection for surgery and timing for transplantation?. <i>Journal of Hepatology</i> , 1993, 18, 135-136.	1.8	6
245	Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma. <i>Journal of Internal Medicine</i> , 2005, 257, 367-373.	2.7	6
246	Ten-Year Outcome of Radiofrequency Thermal Ablation for Hepatocellular Carcinoma: An Italian Experience. <i>American Journal of Gastroenterology</i> , 2012, 107, 1588-1589.	0.2	6
247	Capecitabine in advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, 1260-1261.	0.4	6
248	Duodenal Histological Findings and Risk of Coeliac Disease in Subjects with Autoimmune Atrophic Gastritis: A Retrospective Evaluation. <i>Digestion</i> , 2021, 102, 615-621.	1.2	6
249	Faecal microbiota transplantation in <i>Clostridioides difficile</i> infection: real-life experience from an academic Italian hospital. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093431.	1.4	6
250	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	4.2	6
251	Circulating prostaglandin E2: a novel potential prognostic biomarker in patients with hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , 2021, 21, 675-682.	1.9	6
252	Circulating MicroRNA-21 and MicroRNA-122 as Prognostic Biomarkers in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. <i>Biomedicines</i> , 2021, 9, 890.	1.4	6

#	ARTICLE	IF	CITATIONS
253	Hormonal treatment of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1991, 12, 402.	1.8	5
254	Role of serum fasting gastrin in screening for hypergastrinemic syndromes in duodenal ulcer disease. <i>Clinical Biochemistry</i> , 1992, 25, 121-124.	0.8	5
255	Consensus statement on diet and gastric cancer. <i>European Journal of Cancer Prevention</i> , 1997, 6, 404-407.	0.6	5
256	Transcatheter arterial chemoembolization in hepatocellular carcinoma. <i>Hepatology</i> , 1998, 28, 1441-1443.	3.6	5
257	Transarterial chemoembolization in Child-Pugh class B patients with hepatocellular carcinoma: between the devil and the deep blue sea. <i>Liver International</i> , 2010, 30, 923-924.	1.9	5
258	Molecular Targeted Therapy in Hepatocellular Carcinoma: Present Achievements and Future Challenges. <i>Digestive Diseases</i> , 2012, 30, 284-288.	0.8	5
259	HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: A true-or-false game. <i>Digestive and Liver Disease</i> , 2017, 49, 321-325.	0.4	5
260	A tricky case of pancreatic arteriovenous malformation: the role of endoscopic ultrasound in the diagnosis of this rare condition. <i>Endoscopy</i> , 2019, 51, 195-196.	1.0	5
261	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , 2021, 13, 592.	1.7	5
262	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 822507.	1.3	5
263	Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter. <i>Updates in Surgery</i> , 2023, 75, 291-303.	0.9	5
264	Real-time determination of gastric juice pH with EndoFaster® for atrophic gastritis assessment. <i>Digestive and Liver Disease</i> , 2022, 54, 1646-1648.	0.4	5
265	Gastric juice CEA levels: importance of age and gastric mucosal damage. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1986, 22, 527-529.	0.9	4
266	Gastric Ulcer and Stomach Aging: Pathophysiology and Clinical Implications. <i>Gerontology</i> , 1988, 34, 297-303.	1.4	4
267	Octreotide and hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2007, 96, 1778-1779.	2.9	4
268	Risk of hepatocellular carcinoma in alcoholic cirrhosis. <i>Liver</i> , 1991, 11, 190-191.	0.1	4
269	Efficacy of teduglutide in a patient with Crohn's disease and short bowel syndrome on enteral nutrition: let's start to think out of the box. <i>Gastroenterology Report</i> , 2019, 7, 459-460.	0.6	4
270	The coeliac stomach: A review of the literature. <i>Digestive and Liver Disease</i> , 2020, 52, 615-624.	0.4	4



#	ARTICLE	IF	CITATIONS
271	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.4	4
272	Molecular Refinement of Clinical Staging in Hepatocellular Carcinoma Patients Evaluated for Potentially Curative Therapies. <i>PLoS ONE</i> , 2011, 6, e23093.	1.1	4
273	SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. <i>Biomarkers in Medicine</i> , 2020, 14, 855-867.	0.6	4
274	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , 2021, 158, 133-143.	1.3	4
275	Granular cell myoblastoma of the esophagus: endoscopic diagnosis and therapy. <i>Gastrointestinal Endoscopy</i> , 1985, 31, 22-23.	0.5	3
276	Letter to the editor. <i>International Journal of Cancer</i> , 1989, 44, 378-382.	2.3	3
277	Aspartic proteinases and gastrin in the diagnosis of gastric cancer and gastric precancerous changes. <i>European Journal of Gastroenterology and Hepatology</i> , 1993, 5, 707-712.	0.8	3
278	Cysteine and glutathione in the liver of patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1996, 25, 123.	1.8	3
279	Effects of N-acetyl-l-cysteine in patients with chronic atrophic gastritis and nonulcer dyspepsia: a phase III pilot study. <i>Current Therapeutic Research</i> , 1997, 58, 724-733.	0.5	3
280	The war of the worlds: metaplastic versus nonmetaplastic atrophic gastritis. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 411-412.	0.5	3
281	MINT31 methylation in gastric noninvasive neoplasia. <i>European Journal of Cancer Prevention</i> , 2012, 21, 442-448.	0.6	3
282	Epstein-Barr virus associated gastric dysplasia: a new rare entity?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 939-944.	1.4	3
283	Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and "normal" liver tissues. <i>PLoS ONE</i> , 2020, 15, e0244356.	1.1	3
284	Differential effects of <i>Helicobacter pylori</i> eradication on oxidative DNA damage at the gastroesophageal junction and at the gastric antrum. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1722-8.	1.1	3
285	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221.	0.4	3
286	Diagnostic and prognostic value of the determination of the aminopropeptide of type III procollagen in patients with primary liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1990, 5, 633-638.	1.4	2
287	A new method for detecting anti <i>Helicobacter pylori</i> antibodies: An analytical and clinical evaluation. <i>Journal of Clinical Laboratory Analysis</i> , 1994, 8, 219-222.	0.9	2
288	Up and down regulation of apoptosis in hepatitis C virus-related liver damage. <i>Journal of Hepatology</i> , 2004, 41, 883-885.	1.8	2

#	ARTICLE	IF	CITATIONS
289	Coffee, chronic diseases and cancer. <i>European Journal of Clinical Nutrition</i> , 2013, 67, 898-898.	1.3	2
290	Gastric fundal splenosis presenting as a stromal tumor and diagnosed by endoscopic ultrasound-guided SharkCore biopsy. <i>Endoscopy</i> , 2019, 51, E160-E161.	1.0	2
291	There is much more to rely on histology than the sole endoscopy tells us. <i>Gut</i> , 2020, 69, 1709-1710.	6.1	2
292	Objective Evidence of Gastro-Esophageal Reflux Disease is Rare in Patients with Autoimmune Gastritis. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 30-36.	0.5	2
293	Recalibrating survival prediction among patients receiving transâ€¢arterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 45-53.	0.2	2
294	HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: still an issue?. <i>Hepatoma Research</i> , 2018, 4, 25.	0.6	2
295	Fatal HBV-related liver failure during lamivudine therapy in a patient with non-Hodgkin's lymphoma. <i>Tumori</i> , 2008, 94, 748-9.	0.6	2
296	Mismatch repair status and gastroâ€¢oesophageal dysplasia: need for a dedicated gastrointestinal pathologist?. <i>Histopathology</i> , 2022, , .	1.6	2
297	Thrice-yearly rhythm of duodenal ulcer disease. <i>Current Therapeutic Research</i> , 1993, 53, 648-653.	0.5	1
298	A reappraisal of the Barcelona Clinic Liver Cancer model: natural history of untreated 'intermediate stage' hepatocellular carcinoma. <i>Journal of Internal Medicine</i> , 2004, 256, 529-530.	2.7	1
299	788 INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA (HCC): TO TACE OR NOT TO TACE?. <i>Journal of Hepatology</i> , 2009, 50, S288-S289.	1.8	1
300	Interleukin 1Î² and tumor necrosis factor-Î± polymorphisms in autoimmune gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 196.	0.8	1
301	Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1639-1640.	1.1	1
302	Adequate Interval For Hepatocellular Carcinoma Surveillance. <i>American Journal of Gastroenterology</i> , 2013, 108, 1174.	0.2	1
303	Lowest Case Fatality Rate for Patients With Acute Pancreatitis Admitted in Gastroenterology Units in Veneto Region, Italy. <i>Pancreas</i> , 2019, 48, 1175-1181.	0.5	1
304	No need of transforming gastroenterology units to covid units at the time of SARS-COV2 infection - a single-center analysis from northern italy. <i>Digestive and Liver Disease</i> , 2020, 52, 1094-1096.	0.4	1
305	Liver Resection for Patients with Intermediate Stage Hepatocellular Carcinoma: Beyond Rigid Staging Systems Towards a More Personalized Therapeutic Approach. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1078-1079.	0.9	1
306	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. <i>Transplant International</i> , 2021, 34, 1325-1327.	0.8	1

#	ARTICLE	IF	CITATIONS
307	Systemic therapies for hepatocellular carcinoma: a recap of the current status. <i>Hepatoma Research</i> , 2018, 4, 10.	0.6	1
308	Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series. <i>Pathology Research and Practice</i> , 2022, 233, 153872.	1.0	1
309	Letter: is female sex really associated with better prognosis in hepatocellular carcinoma?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 669-670.	1.9	1
310	Effects of nizatidine on gastric acid and bicarbonate secretion. <i>Current Therapeutic Research</i> , 1993, 53, 277-284.	0.5	0
311	Gastrin and gastric cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 1993, 5, 184.	0.8	0
312	Determinants of gastritis in an area at high risk of gastric cancer. <i>Gastroenterology</i> , 2000, 118, A754.	0.6	0
313	Screening for gastric malignancies: Field study in an open population at high risk. <i>Gastroenterology</i> , 2000, 118, A258.	0.6	0
314	Resting energy-expenditure (REE) in cirrhotic patients: Role of plasma concentrations of leptin and tumor necrosis factor- $\alpha$ (TNF- $\alpha$ ). <i>Gastroenterology</i> , 2000, 118, A1065.	0.6	0
315	Oxidative DNA damage in ulcerative colitis. <i>Gastroenterology</i> , 2000, 118, A1121.	0.6	0
316	The outcome of low and high grade of chronic atrophic gastritis (CAG) after <i>Helicobacter pylori</i> infection eradication: a 3 years follow-up. <i>Gastroenterology</i> , 2000, 118, A1227.	0.6	0
317	<i>Helicobacter pylori</i> CagA+ve infection increases the oxidative DNA damage of gastric mucosa. <i>Gastroenterology</i> , 2000, 118, A182.	0.6	0
318	TGF- $\beta^2$ and hepatocellular carcinoma. <i>Hepatology</i> , 2008, 47, 1095-1095.	3.6	0
319	The Fate of Barrett's Epithelium Under Acid Suppression Obtained by Medical or Surgical Therapy. <i>Gastroenterology</i> , 2011, 140, S-995.	0.6	0
320	OLGA Gastritis Staging & Intestinal Metaplasia Histochemistry. <i>Gastroenterology</i> , 2011, 140, S-677.	0.6	0
321	Letter: gastric atrophy as a precursor of gastric cancer – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 605-605.	1.9	0
322	Digestive oncology: It's now or never. <i>Digestive and Liver Disease</i> , 2012, 44, 180-181.	0.4	0
323	Letter: coffee and chronic liver damage. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 643-643.	1.9	0
324	<i>Helicobacter pylori</i> Infection – The Link Between Oxidative Damage, Cell Proliferation, Apoptosis, and Gastric Cancer. , 2014, , 1871-1891.		0

#	ARTICLE	IF	CITATIONS
325	Barcelona Clinic Liver Cancer staging and the net benefit of liver resection for patients with hepatocellular carcinoma: a multicentre, cohort study. <i>Digestive and Liver Disease</i> , 2014, 46, e15-e16.	0.4	0
326	Laparoscopic ablation and salvage transplantation for patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, e24.	0.4	0
327	Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, e37.	0.4	0
328	Sa1793 The Unfolded Protein Response and Autophagy in Chronic Liver Diseases, HCC and Metastases. <i>Gastroenterology</i> , 2016, 150, S367-S368.	0.6	0
329	Prothrombotic microparticles and risk of portal vein thrombosis in patients with HCV-related liver cirrhosis who underwent DAA antiviral therapy. <i>Digestive and Liver Disease</i> , 2017, 49, e9.	0.4	0
330	Reply. <i>Liver Transplantation</i> , 2017, 23, 1630-1631.	1.3	0
331	SAT-480-Long-term survivors in patients with hepatocellular carcinoma: An ITA.LI.CA report. <i>Journal of Hepatology</i> , 2019, 70, e844.	1.8	0
332	P.04.11 INTRABILIARY RUPTURE OF ECHINOCOCCAL CYST: A NOT RARE COMPLICATION OF HYDATID DISEASE. <i>Digestive and Liver Disease</i> , 2019, 51, e175-e176.	0.4	0
333	Reply. <i>Hepatology</i> , 2019, 69, 465-466.	3.6	0
334	The concept of time-varying therapeutic hierarchy for patients with hepatocellular carcinoma: a multicenter cohort study. On behalf of the ITA.LI.CA study group. <i>Journal of Hepatology</i> , 2020, 73, S99-S100.	1.8	0
335	Circulating microRNA-21 and microRNA-122: prognosis prediction and correlation with HIF-1alpha in hepatocellular carcinoma patients treated with transarterial chemoembolization. <i>Journal of Hepatology</i> , 2020, 73, S376-S377.	1.8	0
336	Prognostic and diagnostic role of angiogenesis biomarkers in hepatocellular carcinoma treated with chemoembolization. <i>Journal of Hepatology</i> , 2020, 73, S378-S379.	1.8	0
337	New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC. <i>Current Signal Transduction Therapy</i> , 2011, 6, 260-266.	0.3	0
338	Oxidative Damage in Chronic and Acute Liver Disease.. , 1996, , 24-32.		0
339	Title is missing!. , 2020, 15, e0244356.		0
340	Title is missing!. , 2020, 15, e0244356.		0
341	Title is missing!. , 2020, 15, e0244356.		0
342	Title is missing!. , 2020, 15, e0244356.		0